Successful treatment of Candida krusei infection with caspofungin acetate: A new antifungal agent

Critical Care Medicine

Volumn 31, Issue 5, 2003, Pages 1577-1578

  McGee, William T ^a   Tereso, Gary J ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Candida krusei; Caspofungin; Fungemia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CILASTATIN PLUS IMIPENEM; CREATININE; DACTINOMYCIN; FLUCONAZOLE; METHOTREXATE; NYSTATIN; PREDNISONE; VANCOMYCIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CANDIDA KRUSEI; CANDIDIASIS; CASE REPORT; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEVER; FUNGEMIA; HUMAN; INFECTION; MALE; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; FUNGEMIA; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PEPTIDES; PEPTIDES, CYCLIC; PLEURAL EFFUSION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0038242372     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000063145.15336.31     Document Type: Article

References (7)

1. Bachman SP, Patterson TF, López-Rilot JL: In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40:2228-2230
2. Barchiesi F, Schimizzi AM, Fothergill AW, et al: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999; 18:302-304
3. Bartizal K, Gill CJ, Abruzzo GK, et al: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2326-2332
4. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. Wayne, PA, National Committee for Clinical Laboratory Standards, 1997
5. Cancidas (caspofungin acetate) for Injection. Whitehouse Station, NJ, Merck package insert, January 2001
6. Klepser ME: Antifungal resistance among Candida species. Pharmacotherapy 2001; 21:124S-132S.
7. Arathoon E, Gotuzzo E, Noriega L, et al: A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent vs. amphotericin C for the treatment (Tx) of oropharyngeal (OPC) and esophageal (EC) candidiasis in adults. 36th Infectious Disease Society of America Meeting, Denver, CO, November 12-15, 1998, pp 99